|
(V261) |
Inhibition of MPO via sodium thiocyanate reduces atherosclerotic plaque formation as well as inflammation and improves endothelial function |
| |
|
A. Zietzer, S. T. Niepmann, B. Camara, R. Andrié, G. Nickenig, V. Tiyerili (Bonn, Siegburg) |
|
|
Diskussion |
|
(V262) |
Proof of principle and preclinical development of a novel epigenetic heart failure therapy |
| |
|
M. Dewenter, A. von der Lieth, T. He, L. Chen, J. Beckendorf, J. Lewis, M. Hrabe de Angelis, W.-H. Zimmermann, B. Klebl, H. A. Katus, J. Backs (Heidelberg, Neuherberg, Göttingen, Dortmund) |
|
|
Diskussion |
|
(V263) |
Inactivation of SOX9 in cardiac fibroblasts improves cardiac function and reduces cardiac fibrosis and inflammation in mice after myocardial infarction |
| |
|
G. M. Scharf, K. Kilian, J. Cordero, Y. Wang, A. Grund, M. Hofmann, N. Froese, A. Kispert, R. Kist, R. Geffers, K. C. Wollert, G. Dobreva, J. Bauersachs, J. Heineke (Mannheim, Hannover, Braunschweig; Newcastle Upon Tyne, UK) |
|
|
Diskussion |
|
(V264) |
Ibrutinib attenuates IGF-1 mediated activation of cardiac calcium handling |
| |
|
D. Tarnowski, K.-G. Kreitmeier, M. Trum, T. Pukrop, L. S. Maier, C. M. Sag (Regensburg) |
|
|
Diskussion |
|
(V265) |
Carnitine exerts beneficial QT- / APD prolonging effects in vivo and on ex vivo whole heart and cellular levels in transgenic short QT syndrome 1 rabbits |
| |
|
K. Michaelides, L. Mettke, I. Bodi, S. Perez-Feliz, M. Brunner, C. Bode, K. Odening (Freiburg im Breisgau) |
|
|
Diskussion |
|
(V266) |
Organ-specific effects of inhibitors of Sterol-O-Acyl-Transferase-1 on mitochondrial respiration and cellular function |
| |
|
V. Johnson, A. Nickel, M. Kohlhaas, I. Weigand, S. Sbiera, M. Fassnacht, M. Kroiss, C. Maack (Würzburg) |
|
|
Diskussion |
|
(V267) |
DNase I-based therapy suppresses cell-free DNA-associated endothelial damage in a rat model of cardiopulmonary bypass with deep hypothermic circulatory arrest |
| |
|
C. Weber, V. Chobanova, M. Yazdanyar, A. Chekhoeva, A. Jenke, T. Wahlers, P. Akhyari, A. Paunel-Görgülü (Köln, Düsseldorf) |
|
|
Diskussion |
|
(V268) |
Improved clinical outcome of erythrovirus-associated inflammatory cardiomyopathy after telbivudine treatment |
| |
|
U. Kühl, F. M. Fruhwald, F. Escher, C.-T. Bock, H. Pietsch, D. Lassner, H.-P. Schultheiss (Berlin; Graz, AT) |
|
|
Diskussion |
|
(V269) |
The engineered connective tissue model – a multi-parametric, medium-throughput approach for fibrotic target validation and drug screening |
| |
|
G. L. Santos, H. Schröder, A. Ridley, W.-H. Zimmermann, S. Lutz, for the study group: DZHK (Göttingen; London, UK) |
|
|
Diskussion |